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SObjective: Our objective was to investigate the role of clinicopathologic factors as predictors of outcome after
complete pulmonary resection for metastatic colorectal cancer.
Methods: Consecutive patients undergoing radical pulmonary resection for colorectal cancer at our institution
were included in the study. Clinicopathologic variables including sex, age, site and stage of the primary tumor,
disease-free interval, prior hepatic resection, timing of pulmonary metastases, preoperative chemotherapy, type
of pulmonary resection, number, size, and location of pulmonary metastases, and thoracic lymph node involve-
ment were retrospectively collected and investigated for prognostic significance. Survival curves were generated
by the Kaplan-Meier technique and difference between factors were evaluated by the log–rank test.
Results: A total of 127 patients undergoing pulmonary resection between 1997 and 2009 were included in the
study. The median follow-up was 67.1 months. The median overall survival from the time of pulmonary resec-
tion was 48.9 months. The 5-year overall survival was 45.4%. Among all investigated prognostic variables, the
number of pulmonary metastases (1 vs>1) was the most important factor affecting the outcome after pulmonary
resection (5-year overall survival 55.4% vs 32.2%; hazard rate, 1.92; P ¼ .006).
Conclusions: In this study, the presence of a single pulmonary metastasis was a favorable predictor of survival
after complete pulmonary resection for metastatic colorectal cancer. All the other prognostic variables did not
seem to affect survival and should not contraindicate such surgery in clinical practice. However, the study
sample size does not allow us to draw any definitive conclusion, and further investigation of the role of these
prognostic factors in larger series is warranted. (J Thorac Cardiovasc Surg 2013;145:97-103)Earn CME credits at
http://cme.ctsnetjournals.org
Colorectal cancer (CRC) is the second most common ma-
lignancy and the second leading cause of cancer death in
Europe.1 When symptoms first occur, about 20% of CRC
patients are diagnosed with metastatic disease. After cura-
tive resection of the primary tumor, approximately 25%
of patients have a recurrence.2
The recent development of biological agents has drasti-
cally enhanced the therapeutic options for patients withmet-
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The Journal of Thoracic and Cand prolonged survival. Moreover, the practice of radical
surgery even in the metastatic setting has converted a tradi-
tionally unfavorable condition into a potentially curable
disease. The number of patients amenable to curative resec-
tion of metastases has increased. Higher response rates,
owing to new combination regimens, greatly increased the
ability to render resectable an initially unresectable disease.3
Themost commonsite of recurrence is the liver, andhepatic
resection is a widely established curative option, with sur-
vivals approaching 60% in highly selected series.4 The lung
is less frequently involved, with only 10% of CRC patients
having pulmonarymetastases.5 Curative pulmonary resection
has also emerged as a safe and effective procedure. Recent im-
provements in the perioperative care and surgical techniques
have significantly reduced the operative mortality from such
surgery to less than 1%. Recent retrospective studies have re-
ported 5-year survivals higher than 50% in patients surgically
treated for isolated pulmonary metastases.6
Nevertheless, relative to hepatic resection, pulmonary re-
section is more questioned and less practiced as a routine
surgical procedure, with palliative treatments often favored.
Indeed, less information is available about its real impact on
the outcome of patients with metastatic CRC, and prognos-
tic factors predicting tumor recurrence after pulmonary
surgery are still to be completely elucidated.6ardiovascular Surgery c Volume 145, Number 1 97
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CI ¼ confidence interval
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icance of a history of hepatic metastases.7 Few studies spe-
cifically addressing this controversial issue have been
published.8-13 In most of them, the survival benefit
derived from resection of pulmonary metastases does not
seem to be negatively affected by a previous surgical
procedure. However, the retrospective design and the
absence of a comparable comparison group with sufficient
statistical power are important limitations.
Through the retrospective analysis of consecutive pa-
tients who underwent pulmonary resection at a single cen-
ter, we aimed to clarify the prognostic impact of a number
of clinicopathologic variables on the outcome of patients
undergoing radical pulmonary resection for metastatic
CRC. We also focused on the prognostic significance of
synchronous or metachronous hepatic metastases.PATIENTS AND METHODS
We retrospectively reviewed the medical records of all the patients
treated with surgery for pulmonarymetastases fromCRC at Istituto Clinico
Humanitas, Rozzano (Italy). Patients were included in the analysis only if
(1) they had undergone colorectal resection before the time of pulmonary
resection, (2) pulmonary resection was performed with a curative intent,
and (3) pathologic analysis of the resected pulmonary tissue had clearly
documented a diagnosis of metastatic deposit from CRC. Patients with re-
sidual disease after pulmonary surgery, patients with a history of surgery
for metastatic disease other than hepatic and pulmonary, and patients un-
dergoing pulmonary resection in the presence of hepatic metastases not
amenable to a simultaneous or staged surgical procedure were excluded
from the analysis.
For all patients fulfilling the inclusion criteria and deemed suitable for
analysis, we collected the following characteristics: sex, age, site and stage
of the primary tumor, presence/absence of pulmonarymetastases at diagno-
sis, disease-free interval from the time of colorectal surgery, previous
hepatic surgery, chemotherapy before pulmonary resection, type and aim
of pulmonary resection, surgical complications, number, size, and location
of pulmonary metastases, thoracic lymph node involvement, hospital stay
after surgery, and date of last contact or death.
Given the rising interest in the possible prognostic role of a prior hepatic
resection, we also analyzed in detail the baseline characteristics and
survival outcome of patients with a history of hepatic metastases. To this
aim, all the patients included in the study were separated into 2 groups.
Group A included patients who had isolated pulmonary metastases and re-
ceived pulmonary resection as the first surgical approach to metastatic
disease. Group B included patients who had a history of hepatic metastases
and received hepatic resection before or concurrent with pulmonary resec-
tion. For this subgroup analysis, hepatic and pulmonary resections were
considered as synchronous when performed in a 1-stage surgical procedure
or, if performed in a 2-stage procedure, when the second metastasectomy
was carried out within 3 months from the time of the first metastasectomy.
During the study period, patient selectionwas carried out individually. In
general, the indication for pulmonary surgery was given when preoperative98 The Journal of Thoracic and Cardiovascular Surgeimaging ruled out extrathoracic and/or unresectable disease and indicated
the possibility to achieve clear resection margins and leave sufficient func-
tioning parenchyma so that the patient had adequate pulmonary reserve for
planned resection and was fit for surgery. Median sternotomy or sequential
thoracotomies were used for patients with bilateral metastases, whereas
video-assisted thoracoscopic surgery was essentially used for peripheral
metastases. Systematic lymph node dissection was not routinely carried
out but was performed according to the surgeon’s judgment.
After pulmonary resection, patients were usually given a follow-up pro-
gramwithoutpatient visits every3months for thefirst 2 years, every6months
for the following 3 years, and every 12months thereafter. At every outpatient
visit, chest radiography or chest computed tomography and/or an abdominal
ultrasound or computed tomography were carried out for surveillance of
thoracic and extrathoracic relapse, respectively. Hematology, biochemistry,
and serum carcinoembryonic antigen were routinely checked at every visit.
Statistical Analysis
Objectives of this study were to identify predictive factors of outcome in
patients undergoing radical pulmonary resection for metastatic CRC.
Patient demographic and clinical characteristics were reported descrip-
tively. For the analysis of the prognostic role of hepatic metastases,
differences between patients in group A and patients in group B were tested
by c2 or Mantel-Haenszel c2 test when appropriate.
Overall survival was calculated from the date of pulmonary surgery to
death (if alive, patients were censored at the time of the last contact). In
case of bilateral or 2-step pulmonary resections and synchronous hepatic
and pulmonary surgery, metrics were calculated from the time of the
second resection. In the case of patients lost to follow-up, the survival status
was corroborated by using the local registry offices or through a first-degree
relative contact.
For the identification of prognostic factors, survival curves were gener-
ated by using Kaplan-Meier technique and differences between factors
were evaluated by the log–rank test. Statistically significant variables
were tested in a multivariate Cox proportional hazards regression model.RESULTS
From April 1997 to September 2009, a total of 185 pa-
tients underwent surgical resection for pulmonary metasta-
ses from CRC at our institution. Thirty-six patients were
excluded from the study because of the palliative or
diagnostic intent of resection and residual disease after tho-
racotomy. Eleven patients were excluded because they had
had a previous operation for a metastatic deposit other than
hepatic and pulmonary. Eleven patients were excluded
because their first thoracotomy had been performed at a dif-
ferent institution and complete clinicopathologic data were
not available. Overall, 127 patients fulfilled the inclusion
criteria and were then suitable for the analysis.
Patient characteristics are listed in Table 1. There were 79
(62%) men and 48 (38%) women. The median age was
65.5 years. More than 25% of patients originally had met-
astatic disease (half of them with pulmonary metastases); in
the other 53% metastases developed more than 1 year after
colorectal surgery. At least 1 chemotherapy regimen was
administered to 43% of patients before the time of pulmo-
nary resection (range, 0-4). Ten (8%) patients had preoper-
ative systemic therapy, 28 (22%) had postoperative therapy,
and only 3 (2%) received a perioperative treatment. Wedge
resection was more frequently used than anatomic resectionry c January 2013
TABLE 1. Patient characteristics
n (%)
All 127 (100)
Sex
Male 79 (62)
Female 48 (38)
Median age (y) (range) 65.5 (33.4-80.6)
Primary site
Colon 78 (61)
Rectum 48 (38)
Colon and rectum 1 (1)
Stage of primary
1-2 35 (28)
3 40 (31)
4 35 (28)
Unknown 17 (13)
Pulmonary metastases at diagnosis
Yes 23 (18)
No 104 (82)
Disease-free interval (mo)
0-12 60 (47)
>12 67 (53)
Chemotherapy lines before resection
0 69 (54)
1 55 (43)
Unknown 3 (3)
History of hepatic metastases
Yes 39 (31)
No 88 (69)
Surgical technique
Anatomic resection* 48 (38)
Wedge resection 79 (62)
No. of pulmonary metastases
1 71 (56)
>1 56 (44)
Site of pulmonary metastases
Unilateral 97 (76)
Bilateral 30 (24)
Size of pulmonary metastases (mm)
0-10 18 (14)
>10 109 (86)
*Include pneumonectomy, (bi)lobectomy, and segmentectomy.
TABLE 2. Univariable analysis of potential predictive factors of
outcome after pulmonary resection
Variable
No. of events
(N)
Five-year overall
survival (95% CI)
P
value
Sex .157
Male 49 (79) 39.0 (26.6-51.4)
Female 25 (48) 56.4 (40.6-72.3)
Age .204
<70 y 51 (86) 52.5 (41.0-64.0)
70 y 23 (41) 23.1 (5.1-41.1)
Primary site .611
Colon 48 (78) 47.5 (35.2-59.8)
Rectum 26 (48) 41.0 (24.3-57.7)
Stage of primary .153
1-2 18 (35) 54.1 (35.8-72.5)
3 25 (40) 44.2 (26.2-62.1)
4 19 (35) 41.9 (23.3-60.4)
Lung metastases at diagnosis .225
Yes 23 (10) 53.4 (30.6-76.3)
No 104 (64) 43.8 (32.9-54.7)
Disease-free interval (mo) .370
0-12 33 (60) 46.1 (31.8-60.4)
>12 41 (67) 44.7 (30.9-58.5)
Chemotherapy lines before
resection
.035
0 37 (69) 56.1 (42.5-69.7)
1 36 (55) 29.6 (15.6-43.5)
Surgical technique .630
Anatomic resection* 28 (48) 49.2 (33.2-65.3)
Wedge resection 46 (79) 43.2 (30.6-55.7)
No. of lung metastases .004
1 36 (71) 55.4 (42.2-68.3)
>1 38 (56) 32.2 (17.9-46.5)
Site of lung metastases .152
Unilateral 52 (97) 48.7 (37.0-60.4)
Bilateral 22 (30) 35.6 (17.5-53.8)
Size of lung metastases (mm) .046
0-10 5 (18) 55.9 (25.6-86.2)
>10 69 (109) 43.5 (33.1-54.0)
Thoracic lymph nodes .118
Normal 38 (67) 46.9 (33.3-60.4)
Metastatic 10 (12) 19.4 (0.0-43.3)
Boldface indicates predictive factors that were statistically significant at univariable
analysis. CI, Confidence interval. *Include pneumonectomy, (bi)lobectomy, and
segmentectomy.
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tion was carried out. A solitary pulmonary lesion was diag-
nosed in 56% of patients, and a predominance of unilateral
pulmonary involvement was observed in 76%. The median
size of pulmonary metastases was 20 mm (range, 5-80 mm)
and most of them (86%) had a maximum diameter greater
than 10 mm.
Median follow-up was 67.1 months (0.4-159.1 months).
At the time of data collection, 74 (58%) of 127 patients
had died. The postoperativemorbidity rate was 12% and in-
cluded only minor self-limiting complications. Two pa-
tients died within 60 days of pulmonary resection, for an
overall postoperative mortality rate of 1.5%. Thirty-three
(30%) patients were alive 5 years after pulmonaryThe Journal of Thoracic and Cresection. The median overall survival was 48.9 months.
The 5-year overall survival was 45.4%.
The univariate analysis of the prognostic factors investi-
gated indicated the number (P¼ .004) and size (P¼ .05) of
pulmonary lesions and the number of prior chemotherapy
lines (P¼ .03) as predictors of outcome after pulmonary re-
section (Table 2).
In a multivariate model including these 3 variables of
interest, only the number of pulmonary lesions retained
its prognostic significance, with a 5-year overall survival of
55.4% in case of a solitary pulmonary lesion versus 32.2%
in case of multiple pulmonary lesions (hazard rate [HR],ardiovascular Surgery c Volume 145, Number 1 99
FIGURE 1. Overall survival after resection of pulmonarymetastases from
colorectal cancer according to the number of pulmonary metastases
(1 ¼ dotted line;>1 ¼ solid line).
TABLE 3. Patient characteristics according to the presence/absence of
a history of hepatic resection
Group A: n (%) Group B: n (%)
P
value
All 88 (100) 39 (100)
Sex .92
Male 55 (63) 24 (61)
Female 33 (37) 15 (39)
Median age (y) (range) 65.5 (34.7-80.6) 65.2 (33.4-80.2) .30
Primary site .16
Colon 51 (58) 27 (70)
Rectum 37 (42) 11 (28)
Colon and rectum 0 (0) 1 (2)
Stage of primary .04
1-2 26 (30) 9 (23)
3 30 (34) 10 (26)
4 18 (20) 17 (43)
Unknown 14 (16) 3 (8)
Pulmonary metastases
at diagnosis
.38
Yes 18 (20) 5 (13)
No 70 (80) 34 (87)
Disease-free interval (mo) .001
0-12 33 (37) 27 (69)
>12 55 (63) 12 (31)
Chemotherapy lines before
resection
0 64 (75) 5 (13) <.001
1 21 (25) 34 (87)
Surgical technique .28
Anatomic resection* 36 (41) 12 (31)
Wedge resection 52 (59) 27 (69)
No. of pulmonary metastases .94
1 49 (56) 22 (56)
>1 39 (44) 17 (44)
Site of pulmonary metastases .92
Unilateral 67 (76) 30 (77)
Bilateral 21 (24) 9 (23)
Size of pulmonary metastases
(mm)
.79
0-10 12 (14) 6 (15)
>10 76 (86) 33 (85)
Thoracic lymph nodes .73
Normal 48 (55) 19 (49)
Metastatic 8 (9) 4 (10)
Unknown 32 (36) 16 (41)
*Include pneumonectomy, (bi)lobectomy, and segmentectomy.
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(Figure 1).
Given the limitations resulting from the relatively small
study sample size, a multivariate model including all
variables presenting a P value<.2 was set. Consistent with
the main analysis, we found that only the number of pulmo-
nary metastases was a statistically significant predictor of
outcome. Furthermore, in the attempt to use clinically mean-
ingful variables as potential risk adjustors, disease-free inter-
val (reported in some studies as a statistically significant
prognostic factor) and size of pulmonary metastases were in-
cluded in the multivariate model despite nonsignificant
P values in the univariate analysis. In this model the number
of pulmonary metastases retained its significance (HR, 1.64;
95%CI, 1.01-2.67;P¼ .044) but,more interestingly, also the
number of chemotherapy lines before pulmonary resection
was found tobe a statistically significant predictor of outcome
(HR, 1.70; CI 95%, 1.04-2.80; P ¼ .036).
When the entire study population was analyzed
according to the presence or absence of a history of hepatic
resection, we observed the following findings. In 88 (69%,
group A) patients, lung was the first site of recurrence
after colorectal surgery and pulmonary metastasectomy
was the first surgical procedure for metastatic disease. In
39 (31%, group B) patients, pulmonary resection followed
(or was synchronous to) a radical operation for hepatic
disease. Owing to their comparable clinical history, 3 pa-
tients who actually had not received a curative hepatec-
tomy were included in the latter group. They were
treated with systemic chemotherapy and had complete re-
sponse in hepatic metastases. In 1 case, no signs of hepatic
disease were appreciable at the time of pulmonary surgery,100 The Journal of Thoracic and Cardiovascular Surg2 years after the first radiologic evidence of complete re-
sponse, and no hepatic surgery was performed. In the other
2 cases, a partial clinical response was obtained but no vi-
able tumor cells were found after hepatic resection for the
residual.
Clinical characteristics of patients in both groups are
listed in Table 3. The 2 groups were well balanced. No sta-
tistically significant differences (P<.05) were observed for
the variables sex, age, number, site and size of pulmonaryery c January 2013
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Slesions, pathologic nodal involvement, surgical techniques,
and hospital stay after pulmonary resection. Patients in
group Bmore often had metastatic disease at the time of ini-
tial diagnosis (43% vs 20%), had had an earlier relapse
after colorectal surgery (69% vs 37% by 12 months), and
had received a greater number of lines of chemotherapy
before the time of pulmonary resection (87% vs 25%).
Characteristics of patients in group B are described in
detail in Table 4. A repeat hepatic resection was necessary
to control hepatic metastases in only 4 patients (2 succes-
sive resections in 3 patients and 3 in 1 patient). Two sequen-
tial surgical procedures (hepatic first and pulmonary later)
were carried out in 31 (79%) patients. In the remaining 8
(21%) patients, hepatic surgery and pulmonary resection
were performed synchronously. In 7 patients a 2-stage sur-
gical procedure was carried out, with pulmonary resection
following hepatic resection in 5 patients. In only 1 patient
was a 1-stage procedure performed.
Median follow-up was 63.2 months (2.0-159.1 months)
for patients in group A and 68.8 months (0.4-98.7 months)
for patients in group B. Postoperative morbidity rate was
16% in group A and 3% in group B, and 1 postoperative
death was recorded in each group. At the time of data collec-
tion, 49 (56%) patients in group A and 25 (64%) patients in
group B had died. Twenty-four (27%) patients in group A
and 9 (23%) in group B were alive 5 years after pulmonary
resection. The median overall survival was 59.4 months for
patients in group A and 30.1 months for patients in group B.
Overall survival at 5 yearswas 51.4% for patients in groupA
and 31.9% for patients in group B. The difference in
outcome between the 2 groups did not reach statistical sig-
nificance (HR, 1.38; 95% CI, 0.85-2.25; P ¼ .19).
DISCUSSION
Although no results of randomized trials are available,
surgery is currently considered, when feasible, the best
option for resectable pulmonary metastases from CRC.TABLE 4. Details of patients with a history of hepatic disease
n (%)
No. of hepatic resections
1 34 (89)
>1 4 (11)
Timing of hepatic and pulmonary resection
Synchronous resection 8 (21)
Metachronous resection 31 (79)
Time from primary resection to pulmonary relapse (mo)
0-12 13 (33)
>12 26 (77)
Median (range) 27 (0-142.4)
Time from hepatic relapse to pulmonary relapse (mo)
0-12 16 (41)
>12 23 (59)
Median (range) 19 (0-107)
The Journal of Thoracic and CaFive-year survivals ranging from 37% to 67% have been
reported in retrospective series.12,14 However, pulmonary
resection is not yet as widely established and frequently
practiced as hepatic resection, and controversy still exists
about its role in the management of metastatic CRC.
Several attempts to identify patients most likely to benefit
from such strategy have been made, but the small number of
patients in most series has limited the identification of
prognostic factors influencing the outcome after resection.6
As a result, the decision for a surgical approach is still
dependent mainly on the conviction and expertise of the sur-
geon rather than on the adherence to established prognostic
criteria.
In this study, we investigated the prognostic role of
a number of clinicopathologic variables previously reported
as potentially predictive of outcome. Consistent with the
results of some studies8,11,12 but in disagreement with the
results of some others,14-16 the number of pulmonary
metastases was the only factor found to independently
predict prognosis, with a significantly better outcome for
patients with a solitary lesion than for patients with
multiple pulmonary lesions. If further confirmed in larger
series, the prognostic significance of pulmonary tumor
burden would influence the diagnostic and therapeutic
algorithm for pulmonary metastasectomy. An accurate
preoperative radiologic assessment of the pulmonary
parenchyma would in fact be necessary to identify the
extent of metastatic pulmonary involvement, the presence
of multiple pulmonary lesions, as well as the presence of
active disease in extrathoracic sites, potentially affecting
the survival benefit deriving from the use of an aggressive
surgical approach. Moreover, in the presence of multiple,
small pulmonary nodules of indeterminate nature and not
amenable to a definitive characterization by imaging, it
would be worth using preoperative medical treatments (ie,
preoperative chemotherapy) aiming at reducing disease
burden and clarifying empirically the extent of pulmonary
disease. Unfortunately, the limited number of patients
who were enrolled in our study and had received
a complementary systemic treatment precluded any
proper investigation of the role of preoperative,
postoperative, or perioperative strategies.
Interestingly, in our study a history of hepatic metastases
did not significantly affect the survival of patients undergo-
ing curative pulmonary resection. To our knowledge, 18
series including more than 30 patients treated with hepatic
and pulmonary resection have been reported so far,8-24
with 5-year survivals, from the time of the second metasta-
sectomy, ranging from 11% to 43.1%. However, only 6
studies have investigated the prognostic impact of a previous
(or synchronous) hepatic operation and the results are not
fully consistent.8-13
In a retrospective series of 47 patients, Kobayashi,
Kawamura, and Ishihara8 reported an actuarial 5-yearrdiovascular Surgery c Volume 145, Number 1 101
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and pulmonary resection, and no significant survival differ-
ence was observed in these patients compared with 304 pa-
tients undergoing pulmonary resection only. Less
promising results were reported by Regnard and col-
leagues.9 In this study, the 5-year survival for patients un-
dergoing sequential surgery (43 patients) was 11% and,
more interestingly, none of the patients in this group was
alive at 6 years, compared with 17% of patients alive at
10 years in the group without hepatic disease. Yedibela,10
Watanabe,11 and their associates reported 2 retrospective
monocentric series of 153 and 122 patients, respectively,
treated with pulmonary metastasectomy. In neither of these
studies was a history of hepatic metastases (reported in 43
and 33 patients, respectively) demonstrated as an unfavor-
able prognostic factor. More recently, in the largest series
ever reported by Onaitis and coworkers12 (378 patients,
166 treated with repeat surgery), the occurrence of a previ-
ous extrathoracic relapse was found to have a trend toward
a negative prognostic influence on outcome after pulmo-
nary resection. Finally, in the recent study by Brouquet
and associates,13 the survival of 112 patients undergoing
hepatic and pulmonary resection was greater than that of
patients receiving hepatic resection only (5-year overall
survival 50% and 40%, respectively), and the presence of
resectable lung metastases was not demonstrated to be
a poor prognostic factor or a contraindication to resection
of hepatic metastases.
All these studies lacked a well-defined control group and
were potentially affected by biases derived from the
retrospective analysis of highly selected patients, deemed
suitable for a repeat resection and possibly yielding a bio-
logically less aggressive tumor with a more favorable
prognosis. Moreover, some of the mentioned studies8,12
recruited patients from different hospitals, with the study
populations likely to be affected by the heterogeneity
derived from receiving treatment at different institutions.
As result of the limited available data and the lack of
strong evidence, the investigators of the Pulmonary Meta-
stasectomy in Colorectal Cancer (PulMiCC) trial (the first
feasibility study to determine whether it is possible to
conduct a larger randomized trial on the role of pulmonary
metastasectomy) included a history of hepatic metastases
into what they called the ‘‘zone of uncertainty.’’25 That is,
a previous (or synchronous) history of hepatic metastases
does not represent an absolute contraindication for a meta-
chronous (or concurrent) pulmonary resection. It should,
however, be taken into consideration and carefully weighed
with other variables when evaluating the individual clinical
benefit derived from a surgical approach to metastatic pul-
monary disease.
In our study, we included consecutive patients treated at
a single institution over a relatively short period. We re-
ported 5-year survivals of 31.9% and 51.4% for the group102 The Journal of Thoracic and Cardiovascular Surgwith a history of hepatic metastases and the group without
a history of hepatic metastases, respectively. The outcome
of either group appeared consistent with that reported in
previous series.10,14,18 More interestingly, the difference
in survival between the 2 groups was not statistically
significant and only a trend toward a worse outcome was
observed for patients with hepatic metastases. Whether
this result truly represents the absence of a prognostic
difference between the 2 groups or is rather affected by
the lack of statistical power of the study is not known. To
analyze the prognostic role of hepatic metastases and
detect a 38% increase in the hazard of death after
pulmonary resection for CRC, we estimated that, with
a power of 80% and an alpha value of .05 (2 sides), at
least 300 deaths would be necessary. The current study is
therefore underpowered (beta > 50%) to detect such
a clinically relevant difference.
Indeed, our analysis is limited by several factors such as
the relatively small number of patients and the retrospective
design. However, the analysis of 2 comparable, homoge-
neous groups with only few imbalances strengthens the
clinical suitability of the results of our study.
In conclusion, the recent increase of the indication for sur-
gical resection of pulmonarymetastases fromCRCwarrants
a careful patient selection based on the identification of reli-
able prognostic factors. Unfortunately, at present no defini-
tive data about predictors of outcome exist. Furthermore,
whether the presence of synchronous hepatic and pulmonary
metastases or the development of pulmonary metastases
after a previous hepatic resection for CRC demonstrate a bi-
ologically aggressive tumor and represent a clear sign of the
failure of an aggressive surgical approach is still unclear.
The results of our study confirm pulmonary resection as an
effective strategy for the treatment of metastatic CRC and
support the number of pulmonarymetastases as themost im-
portant predictor of survival after surgery. Larger series are
probably needed to clarify the prognostic role of other
factors such as a history of hepatic metastases.
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